Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors

Vaccine

Volumn 29, Issue 1, 2010, Pages 34-44

  Hwang, Wonchan ^a   Jung, Keunok ^a   Jeon, Youkyoung ^a   Yun, Shik ^b   Kim, Tae Woo ^c   Choi, Inhak ^a  

^a Inje University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Dendritic cell vaccine; IL 6 receptor; Knockdown

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 6 RECEPTOR ALPHA; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EFFECTOR CELL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GENE KNOCKDOWN TECHNIQUES; INTERLEUKIN-6; INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78649688852     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.027     Document Type: Article

References (29)

1. Bousso P. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat Rev Immunol 2008, 8:675-684.
2. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
3. Kobie J.J., Wu R.S., Kurt R.A., Lou S., Adelman M.K., Whitesell L.J., et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003, 63:1860-1864.
4. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4:941-952.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
6. Frick J.S., Grünebach F., Autenrieth I.B. Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. Int J Med Microbiol 2010, 300:19-24.
7. Sharma M.D., Baban B., Chandler P., Hou D.Y., Singh N., Yagita H., et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007, 117:2570-2582.
8. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000, 1:510-514.
9. Geisel J., Kahl F., Müller M., Wagner H., Kirschning C.J., Autenrieth I.B., et al. IL-6 and maturation govern TLR2 and TLR4 induced TLR agonist tolerance and cross-tolerance in dendritic cells. J Immunol 2007, 179:5811-5818.
10. Hegde S., Pahne J., Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. FASEB J 2004, 18:1439-1441.
11. Kim J.H., Kang T.H., Noh K.H., Bae H.C., Kim S.H., Yoo Y.D., et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett 2009, 122:58-67.
12. Guyre C.A., Gomes D., Smith K.A., Kaplan J.M., Perricone M.A. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies. J Immunol Methods 2008, 333:51-60.
13. Chung S.W., Cohen E.P., Kim T.S. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide. Vaccine 2004, 22:2547-2557.
14. Caldwell S.A., Ryan M.H., McDuffie E., Abrams S.I. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 2003, 171:2402-2412.
15. Jackson S.S., Schmitz J.E., Kuroda M.J., McKay P.F., Sumida S.M., Martin K.L., et al. Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes. Immunology 2005, 116:443-453.
16. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623-2629.
17. Hu L., Shi Y., Hsu J.H., Gera J., Van Ness B., Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003, 101:3126-3135.
18. Zhang J., Li Y., Shen B. PI3-K/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells. Cancer Cell Int 2003, 3:1.
19. Ara T., Declerck Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010, 46:1223-1231.
20. Deng L., Zhang H., Luan Y., Zhang J., Xing Q., Dong S., et al. Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 2010, 16:4105-4112.
21. Sinicrope F.A., Rego R.L., Ansell S.M., Knutson K.L., Foster N.R., Sargent D.J. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137:1270-1279.
22. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
23. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300:339-342.
24. Karbach J., Gnjatic S., Pauligk C., Bender A., Maeurer M., Schultze J.L., et al. Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer 2007, 121:2042-2048.
25. Matsueda S., Takedatsu H., Sasada T., Azuma K., Ishihara Y., Komohara Y., et al. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007, 30:274-281.
26. Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995, 92:8078-8082.
27. Yen M.C., Lin C.C., Chen Y.L., Huang S.S., Yang H.J., Chang C.P., et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 2009, 15:641-649.
28. Toomey D., Conroy H., Jarnicki A.G., Higgins S.C., Sutton C., Mills K.H. Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. Vaccine 2008, 26:3540-3549.
29. Sachdeva M.U., Vankalakunti M., Rangan A., Radotra B.D., Chhabra R., Vasishta R.K. The role of immunohistochemistry in medullomyoblastoma-a case series highlighting divergent differentiation. Diagn Pathol 2008, 3:18.